Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Katen to lead more than PhRMA?

Executive Summary

Pfizer Human Health President Karen Katen is named PhRMA treasurer during the association's annual meeting March 16. Election puts Katen in line to be PhRMA chairman in 2008 and suggests Katen has been selected to replace Pfizer CEO Hank McKinnell, potentially signaling an end to the succession battle at the company (1"The Pink Sheet" Jan. 9, 2006, p. 3). Bristol-Myers Squibb CEO Peter Dolan takes over as 2006 PhRMA chairman, with Amgen CEO Kevin Sharer appointed as the board's chairman-elect...

You may also be interested in...



Welcome To Medicare: Pfizer Sees Part D As Key To Rebirth

The Medicare prescription drug benefit will be a key factor for energizing Pfizer's growth, CEO Hank McKinnell indicated during the Morgan Stanley Pharmaceutical CEOs Unplugged conference in New York Jan. 4

Cosmetic And Personal Care Trademark Review: 16 April

Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.

Health And Wellness Weekly Trademarks Review: 16 April

Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS046990

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel